Donanemab, Eli Lilly’s investigational treatment for Alzheimer's disease, and Arcturus Therapeutics/CSL’s COVID-19 vaccine candidate, ARCT-154, are among the latest products that the European Medicines Agency has started reviewing for potential pan-EU marketing authorization.
Donanemab is an anti-amyloid therapy for slowing disease progression in patients with early symptomatic Alzheimer’s disease. It is also under...








